BEBT-209

N/A

Report date: 2026/04/23 20:00:25
NME

Base Information

Drug NameBEBT-209
Drug Alias NameBEBT-209
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitors
TargetsCyclin-dependent kinase 6Cyclin-dependent kinase 4
Therapy Area/IndicationsMetastatic breast cancerTriple Negative Breast NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGuangzhou BeBetter Medicine Technology Co
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou BeBetter Medicine Technology Co
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerTriple Negative Breast NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A